• Je něco špatně v tomto záznamu ?

Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart

H. S. Kim, J. E. Cho, S. W. Hong, S. O. Kim, J. K. Shim, Y. L. Kwak

. 2010 ; 59 (3) : 347-356.

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc11000401

Remifentanil is a commonly used opioid in anesthesia with cardioprotective effect in ischemia-reperfused (I/R) heart. We evaluated the influence of remifentanil on myocardial infarct size and expressions of proteins involved in apoptosis in I/R rat heart following various time protocols of remifentanil administration. Artificially ventilated anesthetized Sprague-Dawley rats were subjected to a 30 min of left anterior descending coronary artery occlusion followed by 2 h of reperfusion. Rats were randomly assigned to one of five groups; Sham, I/R only, remifentanil preconditioning, postconditioning and continuous infusion group. Myocardial infarct size, the phosphorylation of ERK1/2, Bcl2, Bax and cytochrome c and the expression of genes influencing Ca2+ homeostasis were assessed. In remifentanil-administered rat hearts, regardless of the timing and duration of administration, infarct size was consistently reduced compared to I/R only rats. Remifentanil improved expression of ERK 1/2 and anti-apoptotic protein Bcl2, and expression of sarcoplasmic reticulum genes which were significantly reduced in the I/R rats only. Remifentanil reduced expression of pro-apoptotic protein, Bax and cytochrome c. These suggested that remifentanil produced cardioprotective effect by preserving the expression of proteins involved in anti-apoptotic pathways, and the expression of sarcoplasmic reticulum genes in I/R rat heart, regardless of the timing of administration.

Citace poskytuje Crossref.org

Bibliografie atd.

Lit.: 28

000      
00000naa 2200000 a 4500
001      
bmc11000401
003      
CZ-PrNML
005      
20111210201431.0
008      
110201s2010 xr e eng||
009      
AR
024    7_
$a 10.33549/physiolres.931772 $2 doi
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Kim, H. S.
245    10
$a Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart / $c H. S. Kim, J. E. Cho, S. W. Hong, S. O. Kim, J. K. Shim, Y. L. Kwak
314    __
$a Brain Korea 21 Project Med. Sci. & Anaesth. Pain Res. Inst., Yonsei Univ. Coll. Med., Seoul
504    __
$a Lit.: 28
520    9_
$a Remifentanil is a commonly used opioid in anesthesia with cardioprotective effect in ischemia-reperfused (I/R) heart. We evaluated the influence of remifentanil on myocardial infarct size and expressions of proteins involved in apoptosis in I/R rat heart following various time protocols of remifentanil administration. Artificially ventilated anesthetized Sprague-Dawley rats were subjected to a 30 min of left anterior descending coronary artery occlusion followed by 2 h of reperfusion. Rats were randomly assigned to one of five groups; Sham, I/R only, remifentanil preconditioning, postconditioning and continuous infusion group. Myocardial infarct size, the phosphorylation of ERK1/2, Bcl2, Bax and cytochrome c and the expression of genes influencing Ca2+ homeostasis were assessed. In remifentanil-administered rat hearts, regardless of the timing and duration of administration, infarct size was consistently reduced compared to I/R only rats. Remifentanil improved expression of ERK 1/2 and anti-apoptotic protein Bcl2, and expression of sarcoplasmic reticulum genes which were significantly reduced in the I/R rats only. Remifentanil reduced expression of pro-apoptotic protein, Bax and cytochrome c. These suggested that remifentanil produced cardioprotective effect by preserving the expression of proteins involved in anti-apoptotic pathways, and the expression of sarcoplasmic reticulum genes in I/R rat heart, regardless of the timing of administration.
650    _2
$a financování organizované $7 D005381
650    _2
$a adjuvancia anestetická $7 D000759
650    _2
$a zvířata $7 D000818
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a western blotting $7 D015153
650    _2
$a vápník $x metabolismus $7 D002118
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cytochromy c $x metabolismus $7 D045304
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a hemodynamika $x účinky léků $7 D006439
650    _2
$a homeostáza $7 D006706
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mitogenem aktivovaná proteinkinasa 1 $x metabolismus $7 D019950
650    _2
$a mitogenem aktivovaná proteinkinasa 3 $x metabolismus $7 D048052
650    _2
$a infarkt myokardu $7 D009203
650    _2
$a reperfuze myokardu $7 D015425
650    _2
$a myokard $x metabolismus $x patologie $7 D009206
650    _2
$a fosforylace $7 D010766
650    _2
$a piperidiny $x aplikace a dávkování $x farmakologie $7 D010880
650    _2
$a protoonkogenní proteiny c-bcl-2 $x metabolismus $7 D019253
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a sarkoplazmatické retikulum $x metabolismus $7 D012519
650    _2
$a časové faktory $7 D013997
650    _2
$a protein X asociovaný s bcl-2 $x metabolismus $7 D051028
700    1_
$a Cho, J. E.
700    1_
$a Hong, S. W.
700    1_
$a Kim, S. O.
700    1_
$a Shim, J. K.
700    1_
$a Kwak, Y. L.
773    0_
$w MED00003824 $t Physiological research $g Roč. 59, č. 3 (2010), s. 347-356 $x 0862-8408
856    41
$u http://www.biomed.cas.cz/physiolres/pdf/59/59_347.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 4120 $c 266 $y 7
990    __
$a 20110131162710 $b ABA008
991    __
$a 20110207105710 $b ABA008
999    __
$a ok $b bmc $g 827390 $s 692262
BAS    __
$a 3
BMC    __
$a 2010 $b 59 $c 3 $m Physiological research $x MED00003824 $d 347-356
LZP    __
$a 2011-05/dkme

Najít záznam

Citační ukazatele